Doctor Barred From Treating Patients Served as Expert Witness in UK Cases
· GlobeWire Daily Editorial Desk · Source: www.theguardian.com

A doctor who provided expert medical evidence in criminal cases, including the trial of Lucy Letby, was barred from clinical practice by his employer while those proceedings were ongoing, according to reporting published by the Guardian.
Professor Peter Hindmarsh was excluded from treating patients by the University College London Hospitals NHS Trust (UCLH) in March 2023. Hospital officials cited safety concerns regarding his advice to child patients on insulin. Juries in trials where he testified were reportedly not informed of the restriction.
Impact on Legal Proceedings
- The Thomas Case: In August 2023, Hindmarsh produced an expert report used by the Crown Prosecution Service (CPS) against Damion and Tamara Thomas from Birmingham. Their 12-year-old son, Joshua, died in December 2022 following a severe episode of diabetic ketoacidosis. The parents were subsequently convicted of neglectrelated charges after authorities argued they failed to seek medical help quickly enough.
- Disclosure Issues: Under legal rules, expert witnesses must disclose matters that could undermine their credibility or impartiality, including regulatory investigations. Family representatives stated they and the police were initially unaware of the General Medical Council (GMC) inquiries or the UCLH restriction when Hindmarsh authored his report.
- The Letby Trial: Hindmarsh also served as an expert witness in the trial of neonatal nurse Lucy Letby, where he opined that babies had been poisoned with insulin. The jury in that trial was not told of the GMC investigation or the clinical restrictions.
Regulatory Actions and Resolution
The GMC began investigating Hindmarsh in November 2022 following concerns raised by UCLH and Great Ormond Street Hospital regarding his clinical practice and patient treatment. Rather than facing a final adjudication, Hindmarsh applied for voluntary erasure from the medical register in November 2024, which ended the regulatory investigation without formal conclusions. Representatives for Hindmarsh declined to comment on the findings.



